Journal List > Korean J Obstet Gynecol > v.54(2) > 1088388

Korean J Obstet Gynecol. 2011 Feb;54(2):86-92. Korean.
Published online February 16, 2011.
Copyright © 2011. Korean Society of Obstetrics and Gynecology
Apoptotic effect of NV-196, an isofl avone derivative, in epithelial ovarian cancer cells
Dong Soo Suh, MD,1 Jong Kil Joo, MD,1 Seung Chul Kim, MD,1 Dong Hyung Lee, MD,1 Woo Hee Yi, MD,2 Man Soo Yoon, MD,1 and Ki Hyung Kim, MD1
1Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Busan, Korea.
2Department of Obstetrics and Gynecology, Busan St. Mary's Medical Center, Busan, Korea.

Corresponding author: Ki Hyung Kim, MD. Department of Obstetrics and Gynecology, Pusan National University School of Medicine, 305 Gudeok-ro, Seo-gu, Busan 602-739, Korea. Tel: +82-51-240-7287, Fax: +82-51-248-2384, Email:
Received November 22, 2010; Revised January 20, 2011; Accepted January 31, 2011.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.



The objectives of this study were to determine the efficacy of NV-196, a synthetic isoflavone derivative, as a chemosensitizer in chemoresistant CP70 and R182 epithelial ovarian cancer (EOC) cells and to characterize the mechanism behind its sensitizing effect.


EOC cells were treated with tenfold dilutions of NV-196 (0.1 to 10 µg/mL) for 24 and 48 hours. Cell viability was determined by the CellTiter 96 AQueous One Solution Cell Proliferation Assay. Apoptosis was assessed by Caspase-Glo assays and apoptotic cascade X-linked inhibitor of apoptosis protein (XIAP), caspase-2 and Bid were characterized by Western blot analyses.


As a monotherapy, NV-196 showed decreased cell viability in a time- and dose-dependent manner in both CP70 and R182 cells. A signifi cant increase in caspase-3 activity was observed in both cells. Caspase-8 and -9 activation were also observed. Western blots demonstrated Bid and caspase-2 activation and cleavage of XIAP. NV-196 enhances the cytotoxic effects of carboplatin and paclitaxel.


NV-196 induces cell death through the induction of apoptosis. Pretreatment with NV-196 may sensitize the ovarian cancer cells to carboplatin or paclitaxel. NV-196 may act as a chemosensitizing agent in epithelial ovarian cancer cells.

Keywords: Epithelial ovarian cancer; Isofl avone; NV-196; Paclitaxel; Carboplatin


Fig. 1
(A, B) NV-196 decreases the viability of epithelial ovarian cancer (EOC) cells (CP70 and R182). The viability (in percentage, normalized to untreated cells) of EOC cells after treatment with increasing concentration of NV-196 for 24 and 48 hours. Data were compiled from at least three independent experiments, each done in triplicate (*p<0.05). (C, D) CP70 and R182 cells were pretreated with 10 µg/mL NV-196 for 8 hours and then treated with carboplatin or paclitaxel for 24 hours. Cell viability was determined by the CellTiter 96 AQueous One Solution Cell Proliferation Assay (*p<0.05).
Click for larger image

Fig. 2
(A) Phase-contrast images of NV-196 induced apoptosis in CP70 and R182 cells (×200). Both cells were treated with 10 µg/mL NV-196 for 24 and 48 hours. (B) Hoechst dye staining of apoptotic nuclei (×400), (a) non-treated control, (b) NV-196 treated CP70 cells, 10 µg/mL, 24 hours. NT: non-treated control.
Click for larger image

Fig. 3
Relative caspase-3, -8, -9 activity in CP70 and R182 cells. Cells were exposed to 10 µg/mL NV-196 for 12, 24, 36 and 48 hours. Caspase activity was measured by Caspase-Glo assays as described in Materials and Methods. Y axis: caspase activity fold increase from control. The data were compiled from at least three independent experiments (*p<0.05).
Click for larger image

Fig. 4
Characterization of the apoptotic cascade induced by NV-196. Western blot analyses showing the activation status of anti-apoptotic protein and pro-apoptotic protein after treatment with 10 µg/mL NV-196 for 12, 24, 36, and 48 hours. Results for CP70 and R182 cells are shown.
Click for larger image


This study was supported by a grant of the Korea Healthcare technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (A091177).

1. National Cancer Control Institute (KR). 2008 national cancer statistics. Goyang: National Cancer Center; 2010.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
3. Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC. Current management strategies for ovarian cancer. Mayo Clin Proc 2007;82:751–770.
4. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000;256:42–49.
5. Gross SA, Newton JM, Hughes FM Jr. Decreased intracellular potassium levels underlie increased progesterone synthesis during ovarian follicular atresia. Biol Reprod 2001;64:1755–1760.
6. Saif MW, Tytler E, Lansigan F, Brown DM, Husband AJ. Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers. Expert Opin Investig Drugs 2009;18:469–479.
7. Alvero AB, Brown D, Montagna M, Matthews M, Mor G. Phenoxodiol-Topotecan co-administration exhibit significant anti-tumor activity without major adverse side effects. Cancer Biol Ther 2007;6:612–617.
8. Alvero AB, O'Malley D, Brown D, Kelly G, Garg M, Chen W, et al. Molecular mechanism of phenoxodiol-induced apoptosis in ovarian carcinoma cells. Cancer 2006;106:599–608.
9. Sapi E, Alvero AB, Chen W, O'Malley D, Hao XY, Dwipoyono B, et al. Resistance of ovarian carcinoma cells to docetaxel is XIAP dependent and reversible by phenoxodiol. Oncol Res 2004;14:567–578.
10. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, et al. Characterization of a cis-diamminedichloroplatinum( II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 1987;47:414–418.
11. Kamsteeg M, Rutherford T, Sapi E, Hanczaruk B, Shahabi S, Flick M, et al. Phenoxodiol--an isoflavone analog--induces apoptosis in chemoresistant ovarian cancer cells. Oncogene 2003;22:2611–2620.
12. Peter ME, Scaffidi C, Medema JP, Kischkel F, Krammer PH. The death receptors. Results Probl Cell Differ 1999;23:25–63.
13. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998;94:481–490.
14. Alvero AB, Chen W, Sartorelli AC, Schwartz P, Rutherford T, Mor G. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) induces apoptosis in ovarian cancer cells. J Soc Gynecol Investig 2006;13:145–152.
15. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Cancer Res 2003;63:7081–7088.
16. Li J, Sasaki H, Sheng YL, Schneiderman D, Xiao CW, Kotsuji F, et al. Apoptosis and chemoresistance in human ovarian cancer: is Xiap a determinant? Biol Signals Recept 2000;9:122–130.
17. Tong QS, Zheng LD, Wang L, Zeng FQ, Chen FM, Dong JH, et al. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther 2005;12:509–514.
18. McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S, et al. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene 2004;23:8105–8117.
19. Harlin H, Reffey SB, Duckett CS, Lindsten T, Thompson CB. Characterization of XIAP-deficient mice. Mol Cell Biol 2001;21:3604–3608.
20. Dubrez-Daloz L, Dupoux A, Cartier J. IAPs: more than just inhibitors of apoptosis proteins. Cell Cycle 2008;7:1036–1046.
21. Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ 2006;13:179–188.
22. Johnson DE, Gastman BR, Wieckowski E, Wang GQ, Amoscato A, Delach SM, et al. Inhibitor of apoptosis protein hILP undergoes caspase-mediated cleavage during T lymphocyte apoptosis. Cancer Res 2000;60:1818–1823.
23. Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002;297:1352–1354.
24. Lin CF, Chen CL, Chang WT, Jan MS, Hsu LJ, Wu RH, et al. Sequential caspase-2 and caspase-8 activation upstream of mitochondria during ceramideand etoposide-induced apoptosis. J Biol Chem 2004;279:40755–40761.